ID   647V
AC   CVCL_1049
SY   647-V; 647 V
DR   CLO; CLO_0001450
DR   EFO; EFO_0002098
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-110
DR   BioGRID_ORCS_Cell_line; 500
DR   BioSample; SAMN03473588
DR   BioSample; SAMN10989565
DR   cancercelllines; CVCL_1049
DR   Cell_Model_Passport; SIDM00983
DR   ChEMBL-Cells; CHEMBL3308704
DR   ChEMBL-Targets; CHEMBL1075384
DR   Cosmic; 906797
DR   Cosmic; 928822
DR   Cosmic; 1046676
DR   Cosmic; 1285105
DR   Cosmic; 1286005
DR   Cosmic; 1927309
DR   Cosmic; 2050429
DR   Cosmic; 2057435
DR   Cosmic; 2444239
DR   Cosmic; 2685932
DR   Cosmic-CLP; 906797
DR   DepMap; ACH-000896
DR   DSMZ; ACC-414
DR   DSMZCellDive; ACC-414
DR   EGA; EGAS00001000978
DR   GDSC; 906797
DR   GEO; GSM827156
DR   GEO; GSM886842
DR   GEO; GSM887906
DR   GEO; GSM1374377
DR   GEO; GSM1669570
DR   IARC_TP53; 21152
DR   IGRhCellID; 647V
DR   LiGeA; CCLE_044
DR   LINCS_HMS; 50002
DR   LINCS_LDP; LCL-1708
DR   PharmacoDB; 647V_25_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1049
DR   PubChem_Cell_line; CVCL_1049
DR   Wikidata; Q51951823
RX   DOI=10.1016/B978-0-12-043050-5.50049-4;
RX   PubMed=66978;
RX   PubMed=571047;
RX   PubMed=748774;
RX   PubMed=944089;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=7459858;
RX   PubMed=8873383;
RX   PubMed=15846775;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22460905;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Doubling time: 32 hours (PubMed=66978; PubMed=748774); ~30 hours (DSMZ=ACC-414).
CC   HLA typing: A*02:01; B*27:05,40:01; C*02:02,03:04 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Gln993Ter (c.2977C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 6974; MDM4; Simple; p.Ser161Ter (c.482C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile162Asn (c.485T>A); ClinVar=VCV001408611; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.52%; Native American=0%; East Asian, North=1.95%; East Asian, South=0%; South Asian=0%; European, North=64.01%; European, South=32.52% (PubMed=30894373).
CC   Misspelling: 647B; PubMed=748774.
CC   Discontinued: ATCC; HTB-110; true.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,14
ST   D16S539: 11
ST   D18S51: 13
ST   D19S433: 12
ST   D21S11: 28,30
ST   D2S1338: 24
ST   D3S1358: 16
ST   D5S818: 11
ST   D7S820: 8,11
ST   D8S1179: 12,13
ST   FGA: 20,22
ST   Penta D: 10,11
ST   Penta E: 13
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 18,21
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   DOI=10.1016/B978-0-12-043050-5.50049-4;
RA   Elliott A.Y., Bronson D.L., Cervenka J., Cleveland P.H., Fraley E.E.;
RT   "Establishment and characterization of epithelial cell cultures from
RT   tumors of the human urinary tract.";
RL   (In) Cell culture and the application; Acton R. (eds.); pp.711-728; Academic Press; New York (1977).
//
RX   PubMed=66978;
RA   Elliott A.Y., Bronson D.L., Cervenka J., Stein N., Fraley E.E.;
RT   "Properties of cell lines established from transitional cell cancers
RT   of the human urinary tract.";
RL   Cancer Res. 37:1279-1289(1977).
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=748774;
RA   Elliott A.Y., Bronson D.L., Fraley E.E.;
RT   "Transitional cell cancer: establishment and characterization of cell
RT   lines.";
RL   Natl. Cancer Inst. Monogr. 49:23-24(1978).
//
RX   PubMed=944089;
RA   Elliott A.Y., Bronson D.L., Stein N., Fraley E.E.;
RT   "In vitro cultivation of epithelial cells derived from tumors of the
RT   human urinary tract.";
RL   Cancer Res. 36:365-369(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//